指南与共识胃肠外科急腹症与外科感染围术期管理与 ERAS

EAES-SAGES 临床实践指南更新:憩室病管理关键争议的多学会推荐

EAES-SAGES clinical practice guideline update: multi-society recommendations on key controversies in the management of diverticular disease.
指南 / 共识 · Surg Endosc · 2026-10-14

该指南由 EAES 与 SAGES 联合制定,针对症状性非复杂憩室病、非复杂憩室炎及复杂憩室炎的管理争议,系统评价 27 项研究后采用 GRADE 框架形成推荐。专家组就利福昔明或美沙拉秦、抗生素使用、择期切除及结肠镜随访等提出条件性推荐,并强调以患者为中心的决策。

要点

  • 症状性非复杂憩室病可考虑利福昔明或美沙拉秦而非标准支持治疗。
  • 非复杂憩室炎不建议常规使用抗生素。
  • 复发非复杂憩室炎持续症状者可考虑择期切除而非观察。

核心结论

  • 指南为憩室病管理的关键争议提供了循证推荐,但证据确定性为极低至中等。
  • 推荐均为条件性推荐,需结合患者价值观与偏好进行个体化决策。

研究设计与样本

  • 系统评价纳入 27 项随机试验和队列研究,证据确定性为极低至中等。
  • 国际多学科专家组(胃肠外科医生、消化科医生、患者伙伴及方法学家)采用 GRADE 证据到决策框架达成共识。

主要发现

  • 症状性非复杂憩室病患者,建议利福昔明或美沙拉秦优于标准支持治疗(条件性推荐)。
  • 非复杂憩室炎患者,不建议常规使用抗生素(条件性推荐)。
  • 复发性非复杂憩室炎后持续症状患者,建议择期切除优于观察(条件性推荐)。
  • 首次非复杂憩室炎恢复后,不建议常规随访结肠镜检查(条件性推荐)。
  • 首次憩室炎伴脓肿恢复后,建议择期切除优于监测(条件性推荐)。

关键数值与推荐

  • 症状性非复杂憩室病:建议利福昔明或美沙拉秦(条件性推荐)。
  • 非复杂憩室炎:不建议常规抗生素(条件性推荐)。
  • 复发性非复杂憩室炎持续症状:建议择期切除(条件性推荐)。
  • 首次非复杂憩室炎后:不建议常规结肠镜随访(条件性推荐)。
  • 首次憩室炎伴脓肿后:建议择期切除(条件性推荐)。

临床怎么用

  • 临床决策应纳入患者价值观与偏好,讨论复发风险降低与证据不确定性。
  • 对非复杂憩室炎避免常规抗生素,减少不必要用药。
  • 对特定患者(持续症状的复发性非复杂憩室炎、脓肿后恢复者)可讨论择期切除的获益与风险。

局限性

  • 证据确定性为极低至中等。
  • 缺乏针对优先结局(30 天主要并发症、需急诊手术、1 年无造口生存、1 年生活质量)的证据。
  • 患者价值观和偏好可能差异较大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We identified areas of controversy in the management of patients with diverticular disease to develop key questions addressing the management of symptomatic uncomplicated diverticular disease (SUDD), uncomplicated diverticulitis, and complicated diverticulitis. METHODS: We performed a systematic review to identify randomized trials and cohort studies addressing our key questions. Informed by an updated evidence synthesis, an international, multidisciplinary panel of gastrointestinal surgeons, gastroenterologists, patient partners, and methodologists applied the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework during panel consensus meetings to derive recommendations for the management of patients with diverticular disease. RESULTS: The systematic review identified 27 studies representing very low to moderate certainty evidence. The panel made the following recommendations: 1. In patients with SUDD, we suggest rifaximin or mesalamine over standard supportive care (conditional recommendation); 2. In patients with uncomplicated diverticulitis, we suggest no routine antibiotics (conditional recommendation); 3. In patients with persistent symptoms following an episode of recurrent uncomplicated diverticulitis, we suggest elective resection over observation (conditional recommendation); 4. In patients who have recovered from a first episode of uncomplicated diverticulitis, we suggest no routine follow-up colonoscopy (conditional recommendation); 5. In patients who have recovered from a first episode of diverticulitis complicated by an abscess, we suggest elective resection over surveillance (conditional recommendation). The panel judged that a significant proportion of patients would place a high value in reducing the risk of recurrence at 1 year but also acknowledged the lack of evidence addressing prioritized outcomes including 30-day major complications, need for emergency surgery, stoma-free survival at 1 year, and quality of life at 1 year. Given that patient values and preferences may vary, clinicians are encouraged to apply patient-centered decision-making and discuss the alternatives. CONCLUSION: This clinical practice guideline update provides evidence-informed recommendations to support patients and clinicians in the management of diverticular disease.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Huo B, Al Khaldi M, Shehata D, et al. EAES-SAGES clinical practice guideline update: multi-society recommendations on key controversies in the management of diverticular disease. Surg Endosc. 2026. PMID: 42875633. doi:10.1007/s00464-026-13296-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。